Other Events ·
On August 13, 2026, Cytokinetics filed a complaint in the U.S. District Court for the District of Delaware against…
CYTKCytokinetics Inc
On August 13, 2026, Cytokinetics filed a complaint in the U.S. District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The lawsuit seeks a declaratory judgment that Cytokinetics does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. Cytokinetics also requests preliminary and permanent injunctions preventing defendants from threatening or initiating infringement litigation regarding its MYQORZO (aficamten) product, along with an award of costs and attorneys' fees under 35 U.S.C. § 285. The company demanded a jury trial and stated it intends to vigorously assert its legal rights while noting the inherent uncertainty of litigation outcomes. Cytokinetics operates in the biotechnology industry, focusing on the development of novel cardiac muscle activators for treating heart failure.